<DOC>
	<DOCNO>NCT00399464</DOCNO>
	<brief_summary>The primary objective study demonstrate superiority SL77.0499-10 10mg daily placebo non-inferiority versus tamsulosin hydrochloride 12 week treatment term efficacy patient low urinary tract symptom relate BPH . The secondary objective ass safety SL77.0499-10 patient low urinary tract symptom related BPH comparison placebo tamsulosin hydrochloride .</brief_summary>
	<brief_title>Efficacy Safety SL77.0499-10 ( Alfuzosin ) Versus Placebo Tamsulosin Japanese Patients With Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Japanese ; Having symptomatic BPH diagnose clinically digital rectal examination ultrasonography within last 6 month ; Suffering least 6 month low urinary tract symptom relate BPH . Patients mental disorder rely upon understand trial requirement comply treatment regiment ; Inpatient ; Patients participate clinical trial within previous 6month ; Patients previously treat SL77.049910 ; Patients whose IPSS total score meet â‰¥ 13 ; Patients whose urinary peak flow rate ( PFR ) meet 5.012.0mL/s voided volume least 150mL ; Patients whose residual urine &gt; 200mL ; The investigator evaluate whether reason patient may participate .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Adrenergic alpha-Antagonists</keyword>
	<keyword>alfuzosin</keyword>
</DOC>